» Articles » PMID: 28291383

Investigating Associations Between Health-Related Quality of Life and Endocrine Therapy Underuse in Women With Early-Stage Breast Cancer

Overview
Journal J Oncol Pract
Specialty Oncology
Date 2017 Mar 15
PMID 28291383
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Endocrine therapy (ET) underuse puts women at increased risk for breast cancer (BC) recurrence. Our objective was to determine if health-related quality of life (HRQOL) subgroups were associated with underuse.

Methods: Data came from the third phase of the Carolina Breast Cancer Study. We included 1,599 women with hormone receptor-positive BC age 20 to 74 years. HRQOL was measured, on average, 5 months postdiagnosis. Subgroups were derived using latent profile (LP) analysis. Underuse was defined as not initiating or adhering to ET by 36 months postdiagnosis. Multivariable logistic regression models estimated adjusted odds ratios (ORs) between HRQOL LPs and underuse. The best HRQOL LP was the reference. Chemotherapy- and race-stratified models were estimated, separately.

Results: Initiation analyses included 953 women who had not begun ET by their 5-month survey. Of these, 154 never initiated ET. Adherence analyses included 1,114 ET initiators, of whom 211 were nonadherent. HRQOL was not significantly associated with noninitiation, except among nonchemotherapy users, with membership in the poorest LP associated with increased odds of noninitiation (adjusted OR, 5.5; 95% CI, 1.7 to 17.4). Membership in the poorest LPs was associated with nonadherence (LP1: adjusted OR, 2.2; 95% CI, 1.2 to 4.0 and LP2: adjusted OR,1.9; 95% CI, 1.1 to 3.6). Membership in the poorest LP was associated with nonadherence among nonchemotherapy users (adjusted OR, 2.1; 95% CI, 1.2 to 5.1).

Conclusion: Our results suggest women with poor HRQOL during active treatment may be at increased risk for ET underuse. Focusing on HRQOL, a modifiable factor, may improve targeting of future interventions early in the BC continuum to improve ET initiation and adherence and prevent BC recurrence.

Citing Articles

Describing quality of life trajectories in young Hispanic women with breast cancer: 5-year results from a large prospective cohort.

Vaca-Cartagena B, Ferrigno Guajardo A, Azim Jr H, Rotolo F, Olivas-Martinez A, Platas A Breast. 2025; 79:103866.

PMID: 39753060 PMC: 11755074. DOI: 10.1016/j.breast.2024.103866.


From Race to Racism and Disparities to Equity: An Actionable Biopsychosocial Approach to Breast Cancer Outcomes.

Reeder-Hayes K, Roberson M, Wheeler S, Abdou Y, Troester M Cancer J. 2023; 29(6):316-322.

PMID: 37963365 PMC: 10651167. DOI: 10.1097/PPO.0000000000000677.


Randomized phase III trial evaluating motivational interviewing and text interventions to optimize adherence to breast cancer endocrine therapy (Alliance A191901): the GETSET protocol.

Ivory J, Wheeler S, Drier S, Gunn H, Zahrieh D, Paskett E Trials. 2023; 24(1):664.

PMID: 37828596 PMC: 10568920. DOI: 10.1186/s13063-023-07672-8.


Investigation of Factors Affecting Adherence to Adjuvant Hormone Therapy in Early-Stage Breast Cancer Patients: A Comprehensive Systematic Review.

Yang S, Park S, Bae S, Ahn S, Jeong J, Park K J Breast Cancer. 2023; 26(4):309-333.

PMID: 37272247 PMC: 10475712. DOI: 10.4048/jbc.2023.26.e22.


Trajectories of quality of life in breast cancer survivors during the first year after treatment: a longitudinal study.

Park J, Jung Y, Kim J, Bae S BMC Womens Health. 2023; 23(1):12.

PMID: 36627606 PMC: 9832601. DOI: 10.1186/s12905-022-02153-7.


References
1.
Holt C, Schulz E, Caplan L, Blake V, Southward V, Buckner A . Assessing the role of spirituality in coping among African Americans diagnosed with cancer. J Relig Health. 2011; 51(2):507-21. PMC: 3653318. DOI: 10.1007/s10943-011-9453-0. View

2.
van Londen G, Beckjord E, Dew M, Cooper K, Davidson N, Bovbjerg D . Associations between adjuvant endocrine therapy and onset of physical and emotional concerns among breast cancer survivors. Support Care Cancer. 2013; 22(4):937-45. PMC: 3987952. DOI: 10.1007/s00520-013-2041-y. View

3.
Morales L, Neven P, Timmerman D, Christiaens M, Vergote I, Van Limbergen E . Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients. Anticancer Drugs. 2004; 15(8):753-60. DOI: 10.1097/00001813-200409000-00003. View

4.
Reeder-Hayes K, Wheeler S, Mayer D . Health disparities across the breast cancer continuum. Semin Oncol Nurs. 2015; 31(2):170-7. PMC: 4598050. DOI: 10.1016/j.soncn.2015.02.005. View

5.
Joslyn S, West M . Racial differences in breast carcinoma survival. Cancer. 2000; 88(1):114-23. DOI: 10.1002/(sici)1097-0142(20000101)88:1<114::aid-cncr16>3.0.co;2-j. View